This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?

This study has been completed.
Information provided by (Responsible Party):
L. Jay Katz MD, Wills Eye Identifier:
First received: November 28, 2008
Last updated: November 20, 2016
Last verified: November 2016

A study to determine whether a patient's range of vision test results improve after their eye pressure is lowered by 30% or more by testing on a new machine called the Accumap and how to learn how much the Accumap's results change from one test to another within the same person.

The investigators believe that Multifocal VEP readings (Accumap)(and therefore visual function and ganglion cell function) improve after acutely lowering intraocular pressure.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effect of Acutely Lowering Intraocular Pressure on Multifocal Visual Evoked Potential Testing

Resource links provided by NLM:

Further study details as provided by L. Jay Katz MD, Wills Eye:

Primary Outcome Measures:
  • lowering of intraocular pressure will cause an acute improvement in MfVEP (multifocal visually evoked potential) amplitude readings [ Time Frame: 1 day ]

Enrollment: 23
Study Start Date: October 2004
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
Patients who have received no intervention

Detailed Description:
Accumap testing will be performed before and two to three hours after treatment is initiated to lower IOP. In eye that have bilateral treatment, one eye will be assigned randomly to the study. The mean multifocal objective perimetry amplitude will be compared before and after IOP reduction. Also, the mean amplitudes of five circumferential zones will be compared before and after IOP lowering. Visual field testing and HRT testing will be performed before and after treatment as well if possible. Paired t-tests will be performed no pre-and post-treatment mean MOP amplitude values and circumferential zones to determine statistical significance. A second group of patients whose pressures will not be lowered will also be tested with Accumap at baseline and two hours afterwards, in order to examine reproducibility of mean MOP amplitude and mean circumferential amplitude. HVF and HRT testing will also be obtained on thes patients when possible.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
glaucoma service

Inclusion Criteria:

  • Consecutive patients seen that have their intraocular pressures lowered by at least 30% over the course of two hours.

Exclusion Criteria:

  • Recent (within 6 weeks) intraocular surgery
  • Visual acuity worse than 20/40
  • Pathology unrelated to glaucoma (retinal disease, stroke, brain tumor, etc) associated with visual field defect
  • Prior corneal transplant, corneal edema, or corneal diseases such as keratoconus or dense scarring
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00799994

United States, Pennsylvania
Wills Eye
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Wills Eye
Principal Investigator: L. Jay Katz, MD Wills Eye Institute
  More Information

Responsible Party: L. Jay Katz MD, Glaucoma Service Chief, Wills Eye Identifier: NCT00799994     History of Changes
Other Study ID Numbers: 04-653
Study First Received: November 28, 2008
Last Updated: November 20, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by L. Jay Katz MD, Wills Eye:
intraocular pressure
multifocal visually evoked potentials

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases processed this record on September 19, 2017